Results 41 to 50 of about 6,976 (207)
, 2023 Data and scripts used in "Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases"
Sanderson, Theo, Ruis, Chris
core +1 more source
Use of molnupiravir: A Danish nationwide drug utilization study [PDF]
, 2023 Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19.
Jesper Hallas +13 more
core +1 more source
, 2022 Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses ...
Del Arco, Jon +11 more
core +1 more source
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes [PDF]
, 2023 Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts by inducing mutations in the virus genome during replication.
Alessandra Løchen (9531950) +6 more
core +8 more sources
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
Bulletin of the National Research Centre, 2022 Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 CHUUKESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Molnupiravir antiviral mechanism
, 2021 Molnupiravir, a prodrug of the nucleoside derivative β-D-N 4 -hydroxycytidine (NHC), is currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms involved in molnupiravirinduced mutagenesis had not been explored.
Menéndez-Arias, Luis
core +1 more source
The Lancet Regional Health. Western Pacific, 2023 Summary: Background: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19.
Abraham Ka-Chung Wai +15 more
doaj +1 more source
Viruses, 2022 Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients
Paweł Poznański +8 more
doaj +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 VIETNAMESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core